Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 377, Issue 13, Pages 1217-1227Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1706444
Keywords
-
Categories
Funding
- Merck
- British Heart Foundation [FS/14/55/30806]
- Medical Research Council
- National Institute for Health Research Clinical Research Network
- MRC [MC_UU_12026/5, 1935732, MC_U137686861] Funding Source: UKRI
- British Heart Foundation [FS/14/55/30806] Funding Source: researchfish
- Cancer Research UK
- Versus Arthritis [18475] Funding Source: researchfish
- Medical Research Council [MC_UU_12026/5, MC_U137686861] Funding Source: researchfish
- National Institute for Health Research [RC-PG-0407-10054, NF-SI-0508-10299, NF-SI-0513-10139] Funding Source: researchfish
- Versus Arthritis [20639] Funding Source: researchfish
Ask authors/readers for more resources
BACKGROUND Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [ 10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P = 0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo.
Reviews
Recommended
No Data Available